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Background: Adult T-cell leukemia/lymphoma is a peripheral disease associated with human
T-cell lymphotropic virus type 1. Treatment is carried out according to clinical type with
watchful waiting being recommended for less aggressive types. Aggressive adult T-cell
leukemia/lymphoma is generally treated with chemotherapy and/or antivirals. The objec-
tive  of this study was to correlate the survival of patients diagnosed in Bahia, Brazil, with
the  therapeutic approaches employed and to evaluate what issues existed in their treatment
processes.
Methods: Eighty-three adult T-cell leukemia/lymphoma patients (26 smoldering, 23 chronic,
16  acute, 13 lymphoma and ﬁve primary cutaneous tumoral) with available data were
included in this study.
Results: Complete response was achieved in seven smoldering patients with symptomatic
treatment, in two with chronic disease using antivirals/chemotherapy, in one with acute
disease using antivirals and in one lymphoma using the LSG15 regimen [vincristine,
cyclophosphamide, doxorubicin, and prednisolone (VCAP); doxorubicin, ranimustine, and
prednisolone (AMP); and vindesine, etoposide, carboplatin, and prednisolone (VECP)]. Smol-
dering  patients who received symptomatic treatment presented longer survival. Favorable
chronic patients treated with antivirals presented longer survival compared to the unfa-
vorable subtype. However, for the acute form, ﬁrst-line chemotherapy was  better, albeit
without signiﬁcance, than antivirals. Only one of the patients with lymphoma and primarysponded.cutaneous tumors rePlease cite this article in press as: Oliveira PD, et al. Adult T-cell leukemia/lymphoma treatment in Bahia, Brazil. Rev Bras Hematol Hemoter.
2016. http://dx.doi.org/10.1016/j.bjhh.2016.09.012
Conclusions: Watchful waiting associated with phototherapy represents the best option for
smoldering adult T-cell leukemia/lymphoma with survival in Bahia being superior to that
described in Japan. There was a trend of better results with zidovudine/interferon-alpha in
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favorable chronic disease. Excellent results were achieved in the lymphoma type treated
with the LSG15 protocol. Patients are diagnosed late probably due to lack of knowledge of
adult  T-cell leukemia/lymphoma by primary healthcare doctors and a Brazilian treatment
protocol needs to be established.
©  2016 Associac¸a˜o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by  Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND licenseIntroduction
Human T-cell lymphotropic virus type 1 (HTLV-1) is endemic
in southwestern Japan, sub-Saharan Africa, South America
and the Caribbean with foci in the Middle East and Australo-
Melanesia.1 A seroprevalence study in the general population
of Salvador, Bahia, Brazil showed a rate of 1.7% of HTLV-1
infected individuals.2
Although the majority of HTLV-1 carriers remain asymp-
tomatic, around 10% develop serious diseases such as
adult T-cell leukemia/lymphoma (ATL), HTLV-1-associated
myelopathy/tropical spastic paraparesis (HAM/TSP), HTLV-1-
associated uveitis and infective dermatitis associated with
HTLV-1 (IDH).3 ATL is an aggressive lymphoproliferative dis-
ease of peripheral T cells characterized by short survival and
a poor response to chemotherapy.4
Diagnostic criteria for ATL include positive serology for
HTLV-1 and a histologically or cytologically proven periph-
eral T-cell malignancy. Whenever possible, the HTLV-1 proviral
integration analysis should be performed, except in clinically
and morphologically straightforward cases when it is unlikely
that conﬁrmation of HTLV-1 viral integration is necessary
for diagnosis.5,6 In endemic areas, it is rare that HTLV-1-
associated lymphomas do not exist in seropositive patients.5
Due to diverse presentations, ATL is classiﬁed into ﬁve
clinical types: smoldering, chronic, acute, primary cutaneous
tumoral (PCT) and lymphoma (Table 1).4,7
The most aggressive forms of ATL are the acute, lymphoma,
PCT and unfavorable chronic forms. Smoldering and the favor-
able chronic forms of ATL are less aggressive.5
Difﬁculty in the treatment of ATL is essentially due
to chemotherapy resistance and the immune dysregulation
caused by HTLV-1 infection making the patients more  suscep-
tible to other infections.8,9
The treatment is performed according to the clinical form.
It is recommended to manage patients with less aggressive
forms using supportive care, with a watchful waiting approach
or antivirals with zidovudine (AZT) and interferon-alpha (IFN-
) being the most used. In aggressive ATL, patients are
generally treated with chemotherapy, antivirals and/or bone
marrow transplantation. Other treatment protocols are being
tested such as monoclonal antibodies and arsenic trioxide.5Please cite this article in press as: Oliveira PD, et al. Adult T-cell leukemi
2016. http://dx.doi.org/10.1016/j.bjhh.2016.09.012
Objective
The aim of this study was to correlate survival with treat-
ment approaches for the ﬁve different clinical types in Bahia,(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Brazil and to evaluate what issues existed in their treatment
processes.
Methods
Patient  characteristics
This was a cohort study of 83 ATL patients whose data were
obtained in an ATL database of the Pathology Department of
the University Hospital of the Universidade Federal da Bahia
(UFBA). The majority of patients were diagnosed, treated and
followed-up in the Hematology, Dermatology and Pathology
Departments of the hospital. Most of these patients were
dependent on the Brazilian National Health System (NHS), but
21 had health insurance plans and came from private hospi-
tals or outpatient services of Salvador, Bahia for pathological
reviews and study admission. Patients were diagnosed accord-
ing to preexistent criteria.5 In patients with more  prolonged
survival or with less than 19 years of age, HTLV-1 proviral inte-
gration was investigated using Southern blot or long-inverse
polymerase chain reaction (PCR)10,11 and all of them presented
monoclonality. All patients were human immunodeﬁciency
virus (HIV) negative.
Initially we had 101 patients diagnosed with ATL but 18
were ineligible for the study due to short survival or short
treatment duration (< 1 month). Of the 83 selected patients,
55 lived in Salvador and 28 in the interior of Bahia. Mean
disease duration (time elapsed from beginning of symptoms
until diagnosis) was 24 months, 54.2% of patients were female,
median age was 49.4 years (range: 9–84 years) and there was
a predominance of Afro-descendants (88%). The study group
was composed of 26 smoldering, 23 chronic (16 favorable
and seven unfavorable), 16 acute, 13 lymphoma and ﬁve PCT
patients. All the smoldering patients were non-leukemic, did
not have pulmonary involvement and presented skin lesions.
ATL association with HAM/TSP occurred in 14 patients (16.9%).
Treatment
Overall, 33 patients received ﬁrst-line multiagent chemother-
apy alone, 27 patients received ﬁrst-line antiviral therapy
alone, and four patients received chemotherapy associated
to antiviral therapy as ﬁrst-line therapy. Nineteen smol-
dering ATL patients were initially managed with watchfula/lymphoma treatment in Bahia, Brazil. Rev Bras Hematol Hemoter.
waiting, phototherapy, corticosteroids or radiotherapy. Pho-
totherapy was made with narrow-band ultraviolet B (Nb-UVB)
or psoralen and ultraviolet A (PUVA) applied 2–3 times per
week, with an average of 109 sessions (minimum of 60 and
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Table 1 – Clinical classiﬁcation of adult T-cell leukemia/lymphoma.4,7
Forms Lymphocytosis Abnormal lymphocytes (%) LDH levels Hypercalcemia Involved organs
Smolderinga Absent <5 or ≥5 ≤1.5 × N Absent With or without skin/lung lesions
PCT Absent <5 ≤1.5 × N Absent Skin
Chronicb Present Present ≤2 × N Absent Any organ except bone, GIT and CNS
Lymphoma Absent ≤1 Variable May occur Lymph nodes and any other organ
Acute Usually present ≥5 >1.5 × N May occur Any organ
a Subtyped into leukemic (≥5%) and non-leukemic (<5%) according to abnormal lymphocytes percentage.
b Subtyped into favorable and unfavorable according to the serum levels of albumin, urea nitrogen, and lactic dehydrogenase (LDH).
PCT: primary cutaneous tumoral; N: normal value; GIT: gastrointestinal tract; CNS: central nervous system.
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ﬁrst-line chemotherapy was superior to those who  received
simultaneously chemotherapy and AZT/IFN-,  with a sta-aximum of 115). The type of phototherapy was chosen
ccording to the degree of inﬁltration of the skin lesions.
nly three smoldering patients received either multiagent
hemotherapy or etoposide alone due to generalized exfolia-
ive erythroderma.
Antiviral therapy consisted of a combination of AZT,
roduced by the Institute of Pharmaceutical Technology (Far-
anguinhos/FIOCRUZ), and IFN- provided by the NHS for
ome administration. The type of IFN-, 2a or 2b, given to
atients varied over the years. Currently, IFN- 2a is manufac-
ured by Sheyang Lo Sunshine Pharmaceutical Co., Ltd (China)
nd IFN- 2b by the Institute of Technology in Immuno-
iology Bio-Manguinhos, FIOCRUZ. Both types are lyophilic
ntramuscular/subcutaneous injections provided in ampoules
ith 3,000,000 IU.
Chemotherapy consisted of cyclophosphamide, doxoru-
icin, vincristine, and prednisone (CHOP) and CHOP-like
egimens with doses adjusted depending on the clinical con-
ition of the patient; one patient was treated with a Japanese
rotocol of chemotherapy.12 Patients who evolved with dis-
ase progression while using antiviral therapy received
hemotherapy. Moreover, patients who evolved with dis-
ase progression after ﬁrst-line chemotherapy received either
alvage chemotherapy or salvage antiviral therapy. Only
ne patient was submitted to bone marrow transplanta-
ion.
Clinical and laboratorial exams, as well as imaging tests
ultrasound or computed tomography, X-ray or chest com-
uted tomography) were used to evaluate treatment response.
tatistical  analysis
he data were analyzed using the IBM Statistical Program for
he Social Sciences (SPSS) Software v20.0. The median sur-
ival time (MST) was calculated by the Kaplan–Meier method,
nd the log-rank method was used to compare the differences
etween the various groups. For statistical purposes, a p-value
0.05 was considered signiﬁcant.
thical  aspects
he Research Ethics Committee (CEP) of the University Hospi-
al of the Universidade Federal da Bahia (UFBA) approved thePlease cite this article in press as: Oliveira PD, et al. Adult T-cell leukemi
2016. http://dx.doi.org/10.1016/j.bjhh.2016.09.012
esearch project.Results
First-line  treatment
Complete response was achieved in seven smoldering patients
with symptomatic treatment, in two favorable chronic
patients (one treated with antiviral therapy alone and one with
chemotherapy alone), in one acute case treated with antivi-
ral alone and in one lymphoma case treated with a Japanese
protocol.12
On comparing the 19 smoldering patients who initially
were submitted to symptomatic treatment alone, with the
seven others who received speciﬁc treatment for ATL, the
former presented a longer survival (169 months vs.52 months;
p-value = 0.1164) (Figure 1). Of those who  received symp-
tomatic treatment, only 12 were submitted to phototherapy,
seven of whom achieved complete response and four partial
response. The smoldering patient who received multiagent
chemotherapy had a shorter survival in relation to those who
received antivirals or etoposide alone (Table 2). The patient
who received etoposide for three months and later AZT/IFN-
 or just IFN-, irregularly for another seven years achieved
complete remission with a survival of 240 months. The other
patient who received etoposide during 12 months and, due to
disease progression, was treated with AZT/IFN-  had partial
response and survived 36 months.
The overall MST was 18 months with the acute, lymphoma,
PCT and unfavorable chronic forms having shorter survival
(Table 2).
The MST of the favorable chronic patients who  received
ﬁrst-line antiviral therapy (44 months) was longer, albeit with-
out statistical signiﬁcance, to those who received ﬁrst-line
chemotherapy (36 months) or ﬁrst-line antivirals associated to
22 months of chemotherapy (p-value = 0.465, p-value = 0.0069
and p-value = 0.177, respectively). In contrast, unfavorable
chronic patients who received 11 months of ﬁrst-line
chemotherapy had a longer MST, though non-signiﬁcant,
than those who received six months of ﬁrst-line antivirals
or six months of chemotherapy associated with antivirals (p-
value = 0.198, p-value = 0.157 and p-value = 0.639).
In the acute form, the MST of the patients who  receiveda/lymphoma treatment in Bahia, Brazil. Rev Bras Hematol Hemoter.
tistically signiﬁcant difference (11 months vs. two months;
Please cite this article in press as: Oliveira PD, et al. Adult T-cell leukemi
2016. http://dx.doi.org/10.1016/j.bjhh.2016.09.012
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Figure 1 – Survival curves of speciﬁc and symptomatic treatments for smoldering adult T-cell leukemia/lymphoma.
Table 2 – First-line therapy and survival in 83 patients
with adult T-cell leukemia/lymphoma according to
clinical type.
Clinical type First-line therapy n MST
Smoldering Skin  directed therapies 19 169
AZT/IFN- 4 52
Chemoa 1 4
Ectoposide alonea 2 36
Total 26 109
Favorable chronic AZT/IFN-  9 44
Chemo 6 36
Chemo + AZT/IFN- 1  22
Total 16 42
Unfavorable chronic AZT/IFN 4 6
Chemo 2 11
Chemo + AZT/IFN-  1 6
Total 7 10.5
Acute AZT/IFN- 7 6
Chemo 8 11
Chemo + AZT/IFN-  1 2
Total 16 6
Lymphoma Chemob 12 7
AZT/IFN- 1 15
Total 13 9
Primary cutaneous
tumoral
AZT/IFN-  2 4
Chemo 2 15
Chemo + AZT/IFN-  1 28
Total 5 20
Total 83 18
MST: median survival time; AZT: zidovudine; IFN-:  interferon-
alpha; Chemo: multiagent chemotherapy.
a Erythrodermic patients.
b One used the Japanese chemotherapy protocol.p-value = 0.005). Comparing the MST  of the patients who used
only antiviral treatment with those who used only chemother-
apy, no statistically signiﬁcant difference was found (six
months vs. 11 months; p-value = 0.109). Notwithstanding, the
patient with acute ATL treated during ten months exclusively
with AZT/IFN-  achieved a complete response. This patient
was submitted to bone marrow transplantation but died with
post-transplant complications.
Patients with PCT and lymphoma initially received
chemotherapy, AZT/IFN-  or combinations of the two, with-
out response, except for one patient who used six cycles of
the Japanese original LSG15 (VCAP-AMP-VECP) regimen. This
regimen consists of vincristine, cyclophosphamide, doxoru-
bicin, and prednisolone (VCAP); doxorubicin, ranimustine, and
prednisolone (AMP); and vindesine, etoposide, carboplatin,
and prednisolone (VECP) with intrathecal administration of
methotrexate and prednisone as prophylaxis against central
nervous system relapse.12 As ranimustine does not exist in
Brazil, it was substituted by carmustine.
Fifteen (65.2%) of the chronic patients progressed to the
acute form (71.4% of the unfavorable and 62.5% of the favor-
able chronic patients). Four patients with the smoldering form
progressed to chronic and one to the PCT type. Two patients
with lymphoma progressed to the acute form of the disease.
Among the smoldering patients who progressed to the
chronic form, one was treated with chemotherapy followed
by antiviral treatment and died after 169 months due to cere-
bral hemorrhage and disease progression.13 A second patient
of this group who used only antivirals is still alive after 110
months in complete remission and is refusing further treat-
ment. A third patient has refused speciﬁc treatment until nowa/lymphoma treatment in Bahia, Brazil. Rev Bras Hematol Hemoter.
and is alive after 246 months with stable disease.14 Finally, the
fourth patient, alive with a survival of 57 months, used pho-
totherapy with complete remission of the skin lesions after
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ve months with this treatment being halted three years ago
ithout relapse. The patient who progressed to the PCT form
eceived antiviral treatment followed by chemotherapy after
rogression and continued to alternate these treatments until
eath after 46 months.
Radiotherapy was used in two smoldering patients after
rogression to the chronic form and PCT with isolated cuta-
eous lesions. In one case, the irradiated lesions regressed
ompletely leaving scars, even after 20 years of follow-up.14
he other patient had only a partial response, with later pro-
ression and death.13
The favorable chronic patients who  only took AZT/IFN-
 during the course of the disease showed higher MST
hen compared to those who took AZT/IFN-  followed by
hemotherapy and those who took these therapies simulta-
eously (p-value = 0.016 and p-value = 0.046, respectively). In
he unfavorable chronic and acute patients, the comparisons
n the sequence of different treatments showed no statistically
igniﬁcant differences.
The mortality was 81.9% (68 cases), with 15 patients alive
t the end of the study. The cause of death was due to disease
n 72% of the patients, to other causes in 17.6% and to other
nfections in 7.3%. Deaths due to ATL occurred in 17 (80.9%)
hronic (75% of the favorable and 83.3% of the unfavorable
ubtypes), in 15 (93.75%) acute, in all cases of lymphoma and
CT and in three (11.5%) smoldering patients. Two of the smol-
ering patients died due to disease progression and the other
ue to complications of exfoliative erythroderma resistant to
reatment.
iscussion
TL comprises a set of different clinical forms that have dif-
erent evolutions and therapeutic indications, hence the great
mportance of their proper classiﬁcation before any guidance
n therapeutic approaches.
In the smoldering form, the MST  was superior to what
s described in the literature7,15,16 which may be due to the
se of the classiﬁcation proposed by Bittencourt et al.,4 which
eparates patients with tumors or nodules, in a distinct clin-
cal form, the PCT type, unlike Japanese authors.7,15–17 The
atients with the smoldering form died mostly due to other
auses, contrary to what was observed in the other clinical
ypes, including the PCT. In this form, watchful waiting until
isease progression was viewed as the best choice, although
here was no statistically signiﬁcant differences in the MST  of
his group compared to patients treated with speciﬁc thera-
ies. This may be due to the greater number of living patients
censored).
The data of this study are consistent with other authors
or whom targeted therapies were generally believed unneces-
ary for the smoldering form and where watchful waiting was
onsidered the best option.15 It should be remembered that
1 of 19 patients managed with watchful waiting until disease
rogression were submitted to phototherapy, all with a com-Please cite this article in press as: Oliveira PD, et al. Adult T-cell leukemi
2016. http://dx.doi.org/10.1016/j.bjhh.2016.09.012
lete or partial response and that this proved to be an effective
onduct in the present study. Although watchful waiting is
he most recommended in the literature for the smoldering
orm,5 phototherapy seems to be the best approach as it leads 1 6;x x x(x x):xxx–xxx 5
to a complete or partial remission of the cutaneous lesions, as
reported by other authors.15
Patients with the smoldering type who received speciﬁc
treatment had erythroderma and probably this was the reason
for phototherapy. Two took etoposide, with disease progres-
sion in one and complete remission in the other. Treatment
with etoposide associated with phototherapy in the smolder-
ing form is reported to increase survival.15
The second best prognosis was observed in the chronic
form. Some Japanese authors classify the smoldering and
chronic forms as indolent.16 However, it is important to
remember that the chronic form is classiﬁed into favorable and
unfavorable subtypes, with different survivals and responses
to treatment,5 as noted in this study.
The most aggressive forms, lymphoma, acute, unfavorable
chronic, and PCT had lower MST, regardless of the therapeutic
approaches employed.
Considering the ﬁrst-line therapy in chronic and acute
patients, no signiﬁcant differences were observed between
treatment with antivirals or multiagent chemotherapy. In
contrast to this observation, Bazarbachi et al.8 showed that
ﬁrst-line antiviral treatment induces a high rate of remis-
sion and prolongs survival in chronic ATL. Notwithstanding,
in acute ATL, only the patients with initial complete response
presented a prolonged survival (5-year overall survival: 82%)8
as observed in the present study. The worst option for
these ATL types was the simultaneous use of antivirals and
chemotherapy, probably due to overlapping side effects.
The only patient in this series who underwent bone
marrow transplantation died due to post-transplant compli-
cations. Although it is a recommended practice for aggressive
forms of ATL, mortality is still high.18,19
The lymphoma ATL patients did not respond to antivirals
and chemotherapy except one who used a Japanese protocol
of intensive sequenced chemotherapy followed by antiviral
therapy.12 This patient is alive in complete remission after 64
months. In Japan, good results have been obtained with this
protocol.5
Analyzing the treatment of the favorable chronic patients,
they had a higher survival rate with AZT/IFN-, while
the worst response was with the simultaneous use of
chemotherapy and antivirals. In the unfavorable chronic form,
chemotherapy gave better results, but the small number of
cases precluded analysis.
However, it was difﬁcult to analyze the antiviral treatment
response because the treatment was very irregular in at least
50% of patients. It is noteworthy that treatment with antivi-
ral drugs is self-administered at home and subject to poor
adherence; a signiﬁcant number of the patients interrupted
treatment either due to their own decisions or due to medical
advice because of the excessive side effects, particularly with
IFN-. Sometimes, the treatment was temporarily interrupted
owing to problems in getting the drugs that were unavailabil-
ity in the hospital pharmacy as there is a limited amount of
medication available or because patients were unable to travel
to Salvador to pick up the medications.a/lymphoma treatment in Bahia, Brazil. Rev Bras Hematol Hemoter.
Adherence to therapy hindered by the fact that many
patients do not live in Salvador, often have poor socioeco-
nomic status and depend on transportation provided by their
local governments, plus the side-effects and, perhaps, the lack
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of understanding about these effects. On the other hand, there
is the possibility that patients did not use adequate refrigera-
tion to store the products.
In contrast, the chemotherapy treatment was administered
mainly during hospitalization and to a lesser extent, in out-
patient hematologic services. In these cases, only medical
personnel interrupted treatment due to lack of response, but
another treatment plan was soon established. Thus, patients
had continued treatment and assistance. Furthermore, most
patients who received chemotherapy received a CHOP-like
regimen, with reduced dosage, and hence, fewer side effects.
Among other relevant issues, in Brazil, owing to the difﬁ-
culty of access to healthcare services and to ignorance of the
disease by primary care professionals, there was a large gap
(average of 25 months) between the onset of symptoms and
diagnosis of ATL. Unfortunately, the management guide on
infection by HTLV of the Ministry of Health states that mul-
tiagent chemotherapy is the only adjuvant treatment in ATL,
contradictorily with the recent international literature, and,
moreover, does not indicate the best approach for patients
with the smoldering form.20
It is noteworthy that cases of the most severe forms, where
survival is short, did not always have time to begin therapy as
they often died before treatment began or within a month after
starting, aspects that reﬂect both the gravity of ATL and the
delay in diagnosis. In the present series, these facts occurred
in 15 patients, all of whom had lymphoma and acute ATL.
The small number of cases makes it difﬁcult to compare
the treatment of the ﬁve forms of ATL, in particular due to the
lack of a pre-established treatment protocol and thus various
treatment regimens were used.
It is important to emphasize the need for regular mon-
itoring of ATL patients, as some of them progress to more
aggressive forms, even during treatment. In Japan, smolder-
ing ATL progresses to the acute form much more  frequently
than was seen in the current study.15,16 In the chronic form,
a high number of patients (56.2%) of this study progressed to
the acute form as is reported in the literature.16
It was observed that smoldering and favorable chronic ATL
can have a long survival time, even after discontinuing speciﬁc
treatment or phototherapy after remission of disease. This
observation was curious because it is considered that antiviral
treatment does not cure and treatment should be adminis-
tered for an indeﬁnite period, even after the disappearance of
symptoms.21 Even so, these patients should continue being
followed-up.
With this paper, we  hope to get the attention of the public
health organs in order to improve the care of ATL patients
through adequate public health policies.
Conclusions
In the smoldering form, the best approach is watchful waiting
associated with phototherapy until progression of disease.
In the favorable chronic form, there was a trend of better
results with AZT/IFN-  compared to chemotherapy, highlight-Please cite this article in press as: Oliveira PD, et al. Adult T-cell leukemi
2016. http://dx.doi.org/10.1016/j.bjhh.2016.09.012
ing the importance of sub-classifying this form.
Although ATL is always considered a serious disease,
there are patients who  have a long survival with complete
remission. 0 1 6;x  x x(x x):xxx–xxx
Probably due to the lack of knowledge of this disease by
primary healthcare doctors, it takes time for an ATL patient to
be diagnosed.
A Brazilian therapeutic protocol for ATL needs to be estab-
lished. We  believe that more  attention of the public health
organs should be given to ATL in respect to the vertical trans-
mission of HTLV-1 infection in order to reduce this disease in
the future.
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